DMARDs, disease modifying antirheumatic drugs

Three month treatment of reactive arthritis with azithromycin: a EULAR double blind, placebo controlled study
T K Kvien, J S H Gaston, T Bardin, I Butrimiene, B A C Dijkmans, M Leirisalo-Repo, P Solakov, M Altwegg, P Mowinckel, P-A Plan, T Vischer

Annals of the Rheumatic Diseases Sep 2004, 63 (9) 1113-1119; DOI: 10.1136/ard.2003.010710
Markers of inflammation are negatively correlated with serum leptin in rheumatoid arthritis
C Popa, M G Netea, T R D S Radstake, P L van Riel, P Barrera, J W M van der Meer

Annals of the Rheumatic Diseases Aug 2005, 64 (8) 1195-1198; DOI: 10.1136/ard.2004.032243
Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial
C Antoni, G G Krueger, K de Vlam, C Birbara, A Beutler, C Guzzo, B Zhou, L T Dooley, A Kavanaugh

Annals of the Rheumatic Diseases Aug 2005, 64 (8) 1150-1157; DOI: 10.1136/ard.2004.032268
Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis
A Finckh, J F Simard, C Gabay, P-A Guerne

Annals of the Rheumatic Diseases Jun 2006, 65 (6) 746-752; DOI: 10.1136/ard.2005.045062
Circulating soluble E-selectin in early rheumatoid arthritis: a prospective five year study
A Kuuliala, K Eberhardt, A Takala, H Kautiainen, H Repo, M Leirisalo-Repo

Annals of the Rheumatic Diseases Mar 2002, 61 (3) 242-246; DOI: 10.1136/ard.61.3.242
Autoantibody profiling as early diagnostic and prognostic tool for rheumatoid arthritis
V P K Nell, K P Machold, T A Stamm, G Eberl, H Heinzl, M Uffmann, J S Smolen, G Steiner

Annals of the Rheumatic Diseases Dec 2005, 64 (12) 1731-1736; DOI: 10.1136/ard.2005.035691
Longitudinal analysis of citrullinated protein/peptide antibodies (anti-CP) during 5 year follow up in early rheumatoid arthritis: anti-CP status predicts worse disease activity and greater radiological progression
J Rönnelid, M C Wick, J Lampa, S Lindblad, B Nordmark, L Klareskog, R F van Vollenhoven

Annals of the Rheumatic Diseases Dec 2005, 64 (12) 1744-1749; DOI: 10.1136/ard.2004.033571
High dose chemotherapy and syngeneic stem cell transplantation in a patient with refractory rheumatoid arthritis: poor response associated with persistence of host autoantibodies and synovial abnormalities
M van Oosterhout, R J Verburg, E W N Levarht, J D Moolenburgh, R M Barge, W E Fibbe, J M van Laar

Annals of the Rheumatic Diseases Dec 2005, 64 (12) 1783-1785; DOI: 10.1136/ard.2004.034793
Swedish registers to examine drug safety and clinical issues in RA
J Askling, C M Fored, P Geborek, L T H Jacobsson, R van Vollenhoven, N Feltelius, S Lindblad, L Klareskog

Annals of the Rheumatic Diseases Jun 2006, 65 (6) 707-712; DOI: 10.1136/ard.2005.045872
Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study
M E Weinblatt, E C Keystone, D E Furst, A F Kavanaugh, E K Chartash, O G Segurado

Annals of the Rheumatic Diseases Jun 2006, 65 (6) 753-759; DOI: 10.1136/ard.2005.044404

Main menu

DMARDs, disease modifying antirheumatic drugs

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

DMARDs, disease modifying antirheumatic drugs

Pages